// App-Quantinova.ai

OP0118 (2021) : EFFECT OF WITHDRAWING ETANERCEPT OR METHOTREXATE ON PATIENT-REPORTED OUTCOMES IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION ON COMBINATION THERAPY: RESULTS FROM THE SEAM-RA TRIAL

Researchers

Presenter

  • J. Curtis

Principal Investigators

  • E. Karis

  • V. Bykerk

  • G. Kricorian

  • P. Emery

  • P. Haraoui

  • D. Collier

  • B. Stolshek

Medical Centers

  • University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL

  • Amgen Inc, Global Medical, California, United States of America

  • Hospital for Special Surgery Main Hospital, New York, United States of America

  • Amgen Inc, Global Medical, California, United States of America

  • Amgen Inc., Global Biostatistical Science, Thousand Oaks- CA, United States

  • Leeds National Institute for Health Research, Biomedical Research Center at Leeds Teaching Hospitals Trust, LIRMM Leeds University, Division of Rheumatic and Musculoskeletal Disease, Leeds, United Kingdom

  • Rheumatology Institute of Montreal, Department of Medicine, Montreal, Canada

  • Amgen Inc, Global Medical, California, United States of America

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved